Pfizer’s coronavirus vaccine candidate contains a taxpayer-funded, government-developed spike protein technology, so taxpayers should have more of a say over the price of the vaccine, the consumer group Public Citizen says. On Monday (Nov. 9), Pfizer announced its coronavirus vaccine demonstrated 90% effectiveness against COIVD-19 in the first interim analysis of its phase 3 trial. The National Institutes of Health in 2016 found a way to freeze coronavirus spike proteins in the right shape, which helped produce a stronger immune...